Last reviewed · How we verify

NCT01000922

A Single Center, Randomized, Open-Label, Crossover Study, Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro Either in Combination With a Basal Insulin Infusion or With Insulin Glargine Relative to a Standardized Meal in Patients With Type 1 Diabetes

Completed Phase 2 Last updated 28 July 2015
What this trial tests

Phase 2 trial testing Regular Human Insulin in Diabetes Mellitus in 24 participants. Completed in 1 January 2008.

Timeline
1 June 2006
Primary endpoint
1 January 2008
1 January 2008

Quick facts

Lead sponsorBiodel
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment24
Start date1 June 2006
Primary completion1 January 2008
Estimated completion1 January 2008
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Biodel — full company profile →

Who can join

Adults 19 to 70, any sex, with Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Evaluation of post-prandial blood glucose excursions after a standardized meal and pre meal injections of individual doses of the study insulins.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Regular Human Insulin

Trials testing the same drug.

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01000922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing